Edgar Filing: DelMar Pharmaceuticals, Inc. - Form 4

DelMar Phar Form 4 April 24, 202	rmaceuticals, Inc.					
FORM			OMB APPROVAL			
	UNITED STAT	ES SECURITIES AND EXCHANGI Washington, D.C. 20549	COMMISSION OMB Number: 3235-0287			
Check th if no long	aer.		Expires: January 31, 2005			
subject to	5 STATEMENT	OF CHANGES IN BENEFICIAL O SECURITIES	Estimated average			
Section 1 Form 4 o		SECONITIES	burden hours per response 0.5			
Form 5	Filed pursuant	o Section 16(a) of the Securities Excha	•			
obligation may cont	inue Section 17(a) of t	ne Public Utility Holding Company Act				
See Instru		(h) of the Investment Company Act of	940			
1(b).						
(Print or Type I	Responses)					
1. Name and A Bell John K	Address of Reporting Person	2. Ibbael Flame and Flemer of Flaming	5. Relationship of Reporting Person(s) to Issuer			
Den john K		Symbol DelMar Pharmaceuticals, Inc.				
		[DMPI]	(Check all applicable)			
(Last)	(First) (Middle)	3. Date of Earliest Transaction	X_ Director 10% Owner			
CLUTE 720	ADD WEST	(Month/Day/Year)	Officer (give title Other (specify below) below)			
SUITE 720- BROADWA		04/22/2014				
DROID	(Street)	4. If Amendment, Date Original	6 Individual or Joint/Group Filing/Check			
	(Bucce)	Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line)			
	X Form filed by One Reporting Person					
VANCOUV	/ER, A1 V5Z 1K5		Form filed by More than One Reporting Person			
(City)	(State) (Zip)	Table I - Non-Derivative Securities	Acquired, Disposed of, or Beneficially Owned			
1.Title of	2. Transaction Date 2A. I					
Security (Instr. 3)	(Month/Day/Year) Exec any	tion Date, if Transaction(A) or Disposed of (Code (Instr. 3, 4 and 5)	D) Securities Form: Direct Indirect Beneficially (D) or Beneficial			
(111541-0)	•	th/Day/Year) (Instr. 8)	Owned Indirect (I) Ownership			
			Following (Instr. 4) (Instr. 4) Reported			
		(A) or	Transaction(s)			
G		Code V Amount (D) Pr	(Instr. 3 and 4)			
Common Stock	04/22/2014	P 20,000 A \$	$_{5}$ 64,000 D (1)			
Stook		1.2				

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur	le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: DelMar Pharmaceuticals, Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships						
Reporting Owner Hum		Director	10% Owner	Officer	Other			
Bell John K SUITE 720-999 WEST B VANCOUVER, A1 V5Z	Х							
Signatures								
/s/ John Bell	04/24/2014							
<u>**</u> Signature of Reporting Person	Date							

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v). *

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) 29,000 shares are held directly by Mr. Bell and 35,000 shares are held by Onbelay Capital Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.